| Time period of initial prescription |  | ||||
---|---|---|---|---|---|---|
Characteristics | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 | 2015–2016 | All |
(n = 3297) | (n = 4151) | (n = 4927) | (n = 4944) | (n = 3614) | (n = 20,933) | |
Sex (% female) | 2617 (79) | 3267 (79) | 3822 (79) | 3846 (78) | 2751 (76) | 16,303 (78) |
Mean age, years (SD) | 53.7 (15) | 54.9 (15) | 55.7 (15) | 56.2 (15) | 56.9 (15) | 55.6 (15) |
BMI, kg/m2 (mean +/− SD) | 27.3 (6) | 27.4 (6) | 27.6 (6) | 27.8 (6) | 28.4 (6) | 27.7 (6) |
BMI category (%) | ||||||
 Underweight (BMI < 18.5) | 81 (3) | 89 (2) | 95 (2) | 90 (2) | 68 (2) | 424 (2) |
 Normal (BMI 18.5 – < 25) | 1096 (37) | 1371 (36) | 1623 (36) | 1553 (34) | 1054 (31) | 6697 (35) |
 Overweight (BMI 25 – < 30) | 942 (32) | 1274 (34) | 1530 (34) | 1527 (34) | 1139 (33) | 6412 (33) |
 Obese (BMI 30+) | 815 (28) | 1053 (28) | 1271 (28) | 1390 (31) | 1157 (34) | 5686 (30) |
CKD (≥ stage 3) | 213 (7) | 344 (8) | 366 (7) | 366 (7) | 283 (8) | 1572 (8) |
Tamoxifen use | 26 (1) | 47 (1) | 66 (1) | 69 (1) | 54 (2) | 262 (1) |
Diabetes mellitus (%) | 228 (7) | 370 (9) | 483 (10) | 552 (11) | 517 (14) | 2150 (10) |
Smoking status (% current smoker) | 696 (22) | 881 (22) | 977 (20) | 953 (20) | 645 (18) | 4152 (20) |
Indication for HCQ (%) | ||||||
 RA/inflammatory arthritis | 1745 (53) | 2352 (57) | 2794 (57) | 2863 (58) | 2001 (56) | 11,749 (56) |
 SLE | 459 (14) | 462 (11) | 481 (10) | 415 (8) | 283 (8) | 2100 (10) |
 Systemic autoimmune rheumatic diseasea | 117 (4) | 156 (4) | 183 (4) | 174 (4) | 148 (4) | 778 (4) |
 Primary dermatologic disease | 282 (9) | 384 (9) | 489 (10) | 5142 (11) | 486 (13) | 2183 (10) |
 All other indications | 700 (21) | 797 (19) | 980 (20) | 950 (19) | 696 (19) | 4123 (20) |